Dr. Nasser Hanna, Indiana University Health, describes the factors which determine whether stage III NSCLC is resectable.

As part of the series co-sponsored by GRACE and LUNGevity, challenging cases in lung cancer discussed with multiple experts, here's one on the common but vexing scenario of a patient with mediastinal node-positive (stage IIIA N2) NSCLC. This is among the most controversial clinical settings in lung cancer, as illustrated by the wide range of answers of how the experts in this program would manage the same patient. Some of the experts even note that the way that such a patient would be managed at their center would depend on the people weighing in on the case.